U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H2O3.Pt.2H3N
Molecular Weight 303.181
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NEDAPLATIN

SMILES

N.N.[Pt++].[O-]CC([O-])=O

InChI

InChIKey=GYAVMUDJCHAASE-UHFFFAOYSA-M
InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1

HIDE SMILES / InChI

Molecular Formula H3N
Molecular Weight 17.0305
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Pt
Molecular Weight 195.084
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H2O3
Molecular Weight 74.0355
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36857 | https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=468844 | http://www.kegg.jp/medicus-bin/japic_med_product?id=00024597

Nedaplatin is a second-generation cisplatin analogue with antineoplastic activity. nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. It is currently registered for the treatment of various cancers (head and neck, testicular, lung, ovarian, cervical, non-small-cell lung) in Japan. The most commonly reported adverse reactions include nausea, vomiting, loss of appetite and hair loss. Nedaplatin may also cause nephrotoxicity at therapeutic doses, especially in patients with deteriorating renal function.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AQUPLA

Approved Use

Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer.

Launch Date

1995
Primary
AQUPLA

Approved Use

Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer.

Launch Date

1995
Primary
AQUPLA

Approved Use

Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer.

Launch Date

1995
Primary
AQUPLA

Approved Use

Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer.

Launch Date

1995
Primary
AQUPLA

Approved Use

Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer.

Launch Date

1995
Primary
AQUPLA

Approved Use

Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer.

Launch Date

1995
Primary
AQUPLA

Approved Use

Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer.

Launch Date

1995
Primary
AQUPLA

Approved Use

Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer.

Launch Date

1995
PubMed

PubMed

TitleDatePubMed
[Nadaplatin or cisplatin combined with paclitaxol in treatment for non-small cell lung cancer: a randomized controlled study].
2007 Jun
Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.
2007 Jun
[A case of SIADH developed during neoadjuvant chemotherapy using nedaplatin and 5-fluorouracil in a patient with esophageal cancer].
2010 Sep
Patents

Patents

Sample Use Guides

Once daily over 60 minutes or longer, and then it is discontinued for at least 4 weeks. This dosing schedule as 1 course is repeated.
Route of Administration: Intravenous
Nedaplatin inhibited the proliferation of SBC-3 cells by 98%, 93%, 75%, 54%, 27%, 6%, and 2% at a concentration of 0.005, 0.01, 0.025, 0.05, 0.1, 0.25, and 0.5 ug/ml, respectively. Consequently, its IC50 value for growth inhibition of SBC-3 cells was 0.053 ug/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:55:49 GMT 2023
Edited
by admin
on Fri Dec 15 15:55:49 GMT 2023
Record UNII
8UQ3W6JXAN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NEDAPLATIN
INN   JAN   MART.   WHO-DD  
INN  
Official Name English
NSC-375101D
Code English
AQUPLA
Brand Name English
nedaplatin [INN]
Common Name English
CIS-DIAMMINE(GLYCOLATO-O(SUP 1),O(SUP 2))PLATINUM
Common Name English
CIS-DIAMMINE-GLYCOLATOPLATINUM
Common Name English
CDGP
Common Name English
NEDAPLATIN [JAN]
Common Name English
Nedaplatin [WHO-DD]
Common Name English
NEDAPLATIN [MART.]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 753320
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
NCI_THESAURUS C1450
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
FDA ORPHAN DRUG 747220
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
Code System Code Type Description
CAS
95734-82-0
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
DRUG BANK
DB13145
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
MESH
C053989
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
EVMPD
SUB09178MIG
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
WIKIPEDIA
NEDAPLATIN
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
NCI_THESAURUS
C61099
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
INN
6942
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
PUBCHEM
9796440
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
CHEBI
31898
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
FDA UNII
8UQ3W6JXAN
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
SMS_ID
100000084126
Created by admin on Fri Dec 15 15:55:49 GMT 2023 , Edited by admin on Fri Dec 15 15:55:49 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY